RT Journal Article
SR Electronic
T1 PROJECTING A MATURE EPIDEMIC: A SIMPLE TOOL WITH AN APPLICATION TO COVID-19 DEATHS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20152512
DO 10.1101/2020.07.13.20152512
A1 Marc Artzrouni
A1 Randy Wykoff
YR 2020
UL http://medrxiv.org/content/early/2020/07/14/2020.07.13.20152512.abstract
AB We describe a new statistical model for the spread of a mature epidemic, i.e. one characterized by an exponentially decaying growth rate of the cumulative number of cases/deaths – the speed of this decay being measured by the growth rate’s half-life. If such a pattern is observed during the recent past, then it can be extrapolated. A spreadsheet is made available that allows users to input weekly cumulative numbers of deaths and obtain an estimate of the growth rate’s baseline half-life and the corresponding projections. These projections can be compared to those with a larger half-life (if a protracted epidemic is expected, e.g. due to second wave), or with a smaller one (if successful therapies or mitigation efforts reduce transmission). The model is applied to deaths due to COVID-19 in California in May-June 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata and program available